Jefferies Financial Group Inc. Purchases Shares of 508,740 Bristol Myers Squibb Company $BMY

Jefferies Financial Group Inc. purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 508,740 shares of the biopharmaceutical company’s stock, valued at approximately $29,314,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at $48,434,000. MASTERINVEST Kapitalanlage GmbH acquired a new position in Bristol Myers Squibb in the 2nd quarter worth $530,000. Redwood Investment Management LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth about $921,000. Parvin Asset Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $1,109,000. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $360,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BMY has been the subject of several recent research reports. Raymond James Financial assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Jefferies Financial Group lowered Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Roth Capital began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price target for the company. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 5th. Finally, Royal Bank Of Canada lifted their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), BMY’s first-in-class CELMoD therapy, for adults with relapsed or refractory multiple myeloma in combination with Darzalex and dexamethasone. The approval adds a potential oncology growth driver and expands BMY’s treatment portfolio in a major cancer market. New FDA Approval Gives Bristol-Myers Squibb Another Potential Oncology Growth Catalyst
• Positive Sentiment: Zenbexus received accelerated approval based on improved minimal residual disease-negative complete response rates. As the first approved CELMoD therapy in this setting, it could strengthen BMY’s competitive position in multiple myeloma, although continued approval depends on confirmatory evidence. Zenbexus First-in-Class CELMoD Approval
• Positive Sentiment: BMY is extending clinical development of deucravacitinib, signaling longer-term ambitions in autoimmune diseases and potentially broadening its growth pipeline beyond oncology. Bristol Myers Squibb Extends Deucravacitinib Program
• Neutral Sentiment: Camzyos continues to gain momentum, but its ability to offset patent pressures on older products depends partly on an upcoming FDA decision regarding adolescent use and competition from rival heart drugs. Can Camzyos Growth Offset Bristol Myers Patent Pressures?
• Negative Sentiment: BMY ended its Cellares partnership after concluding that the Cell Shuttle platform could not support commercial-scale manufacturing of Breyanzi. The decision raises questions about manufacturing capacity and the pace of Breyanzi growth, despite avoiding further spending under the agreement valued at up to $380 million. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: Senior Vice President Phil Holzer sold 500 BMY shares for approximately $33,750, reducing his holdings by 2.88%. The small transaction is generally a limited signal, but may add modest caution after the stock’s recent advance. Bristol Myers Squibb SVP Sells 500 Shares
• Negative Sentiment: A patent dispute involving Cytokinetics creates additional legal uncertainty around BMY’s products and could increase future litigation or commercial risks. What Does Bristol Myers Squibb Face After Zenbexus Approval and Patent Action?

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Performance

BMY opened at $66.93 on Friday. The business’s 50-day simple moving average is $61.51 and its 200 day simple moving average is $59.64. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market capitalization of $136.73 billion, a PE ratio of 14.74, a PEG ratio of 0.18 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s revenue was up 5.7% compared to the same quarter last year. During the same period last year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.